Next 10 |
home / stock / rvx:cc / rvx:cc news
Calgary, Alberta--(Newsfile Corp. - July 16, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced it has entered into definitive transaction documents for the two-year extension of the Company's US$6.0 million secured convertible debenture (the "Debenture") with Sh...
Calgary, Alberta--(Newsfile Corp. - May 28, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today that its Annual and Special Meeting of Shareholders (the "Meeting") will be held on Wednesday, July 31, 2024, commencing at approximately 1:00 pm (MT), as opposed to a...
Calgary, Alberta--(Newsfile Corp. - May 13, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a two-year extension of the Company's US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of a...
Gold Springs Resource Corp. (GRC:CA) is expected to report for Q1 2024 Primo Water Corporation (PRMW:CA) is expected to report $0.18 for Q1 2024 Greenlane Renewables Inc. (GRN:CA) is expected to report $-0.01 for Q1 2024 Kelso Technologies Inc. (KLS:CA) is expected to report for Q1 20...
Multi-Metal Development Ltd. (MLY:CA) is expected to report for quarter end 2023-12-31 Marimaca Copper Corp. (MARI:CA) is expected to report for Q4 2023 Fury Gold Mines Limited (FURY:CA) is expected to report for Q4 2023 Titan Medical Inc. (TMD:CA) is expected to report for quarter en...
2024-03-27 17:08:02 ET Developing safe, epigenetic therapeutics for people suffering from chronic illnesses Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions...
2024-03-27 17:08:02 ET The future of drug development Resverlogix is committed to developing epigenetic therapies for the benefit of patients with chronic disease. Their current clinical program focuses on advancing their lead compound ( apabetalone) and evaluating its th...
Calgary, Alberta--(Newsfile Corp. - February 21, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announced that Shawn Lu has stepped down from the Board of Directors, effective today. "We would like to thank Shawn for his contributions and wish him all the best," said ...
Calgary, Alberta--(Newsfile Corp. - January 11, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", "the Company") today announced publication of an article, entitled, " The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation in vitro and in a mouse model of systemic ...
Resverlogix Corp. (RVX:CA) is expected to report for Q1 2024 SNC-Lavalin Group Inc. (ATRL:CA) is expected to report $0.37 for Q3 2023 Cascadero Copper Corporation (CCD:CA) is expected to report for quarter end 2023-08-31 Pivotree Inc. (PVT:CA) is expected to report $-0.03 for Q3 2023 ...
News, Short Squeeze, Breakout and More Instantly...
Calgary, Alberta--(Newsfile Corp. - July 16, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced it has entered into definitive transaction documents for the two-year extension of the Company's US$6.0 million secured convertible debenture (the "Debenture") with Sh...
Calgary, Alberta--(Newsfile Corp. - May 28, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today that its Annual and Special Meeting of Shareholders (the "Meeting") will be held on Wednesday, July 31, 2024, commencing at approximately 1:00 pm (MT), as opposed to a...
Calgary, Alberta--(Newsfile Corp. - May 13, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a two-year extension of the Company's US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of a...